Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.56 |
| ▸ | CA6 | P23280 | 5/20 | 0.56 |
| ▸ | CA7 | P43166 | 5/20 | 0.56 |
| ▸ | CA9 | Q16790 | 5/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA4 | P22748 | 4/20 | 0.53 |
| ▸ | CA5A | P35218 | 4/20 | 0.53 |
| ▸ | CA3 | P07451 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1073376 | 1.00 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL27525013 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL9100273 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL9716193 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL3657736 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL1565417 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL863599 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL18288 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL19612785 | 0.94 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL11072809 | 0.94 | CA12 (0.56) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104274414-A | Methylnaltrexone compound, oral tablet and preparation methods of two | TIANJIN KANGHONG PHARMACEUTICAL TECHNOLOGY DEV CO LTD | 2015-01-14 | — | — | CN | claimed |
| CN-101420934-B | Method for stabilizing oxidatively unstable compositions | JOHNSON & JOHNSON VISION CARE | 2014-03-19 | — | — | CN | claimed |
| CN-101808652-A | The ophthalmic solution of stabilisation | JOHNSON & JOHNSON VISION CARE | 2010-08-18 | — | — | CN | claimed |
| CN-101420934-A | Method for stabilizing oxidatively unstable compositions | JOHNSON & JOHNSON VISION CARE (US) | 2009-04-29 | — | — | CN | claimed |
| EP-1606012-A2 | METHODS FOR PROTECTION FROM TOXICITY OF ALPHA EMITTING ELEMENTS DURING RADIOIMMUNOTHERAPY | Sloan-Kettering Institute For Cancer Research (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2005028021-A2 | METHODS FOR PROTECTION FROM TOXICITY OF ALPHA EMITTING ELEMENTS DURING RADIOIMMUNOTHERAPY | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-03-31 | — | — | WO | claimed |
| US-20040191169-A1 | Methods of protection from toxicity of alpha emitting elements during radioimmunotherapy | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-09-30 | — | — | US | claimed |
| US-20250161502-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 225-ACTINIUM-LABELLED COMPLEX AND A BISMUTH SEQUESTERING AGENT | ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L. (IT) | 2025-05-22 | — | — | US | disclosed |
| EP-4475900-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 225-ACTINIUM-LABELLED COMPLEX AND A BISMUTH SEQUESTERING AGENT | Novartis AG (CH) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023152671-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 225-ACTINIUM-LABELLED COMPLEX AND A BISMUTH SEQUESTERING AGENT | NOVARTIS AG (CH) | 2023-08-17 | — | — | WO | disclosed |
| CN-107249327-A | Slow down tumour progression using methyl naltrexone | 萨利克斯药品公司 | 2017-10-13 | — | — | CN | disclosed |
| CN-106163489-A | As the compositions that skin preparations for extenal use or cosmetic preparation are useful | 株式会社高丝 | 2016-11-23 | — | — | CN | disclosed |
| CN-101808652-A | The ophthalmic solution of stabilisation | JOHNSON & JOHNSON VISION CARE | 2010-08-18 | — | — | CN | disclosed |
| EP-1606012-A2 | METHODS FOR PROTECTION FROM TOXICITY OF ALPHA EMITTING ELEMENTS DURING RADIOIMMUNOTHERAPY | Sloan-Kettering Institute For Cancer Research (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005028021-A2 | METHODS FOR PROTECTION FROM TOXICITY OF ALPHA EMITTING ELEMENTS DURING RADIOIMMUNOTHERAPY | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040191169-A1 | Methods of protection from toxicity of alpha emitting elements during radioimmunotherapy | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161502-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 225-ACTINIUM-LABELLED COMPLEX AND A BISMUTH SEQUESTERING AGENT | RAB35, SHBG, SSTR5 | CA12 533/4885CA6 516/4885CA7 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.